Healthcare costs are climbing, GLP-1 drug costs are the flashpoint, and employers and health plans are quietly rewriting how they pay for high-cost drugs. Here is the shift, and the real-time rail that makes it work.
Drug spend is rising faster than almost any line on a benefits budget, and one category, GLP-1s, has become the face of the problem.
Employers want to help people afford these medications. They also cannot write a blank check for a drug that can run more than a thousand dollars a month, for a fast-growing share of their workforce. For years those two goals sat in tension. They do not have to.
While GLP-1s are driving today's conversation, the same model applies to specialty pharmacy programs and other high-cost therapies.
For decades, a drug benefit was an open-ended promise. Whatever the medication cost, the plan paid its share, no matter how high that number climbed. Defined contribution flips it.
The employer commits a fixed amount per member. The member still gets real, predictable help. The employer gets a number it can actually budget. Spend is capped by design, not by denying care.
The companies that make and move these drugs are going direct too. Manufacturers are standing up direct-to-consumer and direct-to-employer channels with transparent cash prices, often well below list, reaching members and employers without the usual layers in between.
That is good for cost. It also means the lowest price for a given drug now lives in more places than ever: a plan, a cash card, a manufacturer's own storefront. Someone still has to find it, and bring the money together, at the moment of purchase.
Defined contributions, direct channels, and stacked funding only add up if something can price, decide, and pay in real time, at the point of sale, down to the exact drug. That is the Lynx Rx Access Wallet. It carries the rules and the money, and it settles the whole thing in about a second.
Unlike traditional benefits infrastructure that was built for claims and reimbursement workflows, the Lynx Rx Access Wallet enables real-time pricing, funding, and payment directly at the point of sale.
Real-time pricing and payment, from a $1,086 list price to a $25 member cost, in about a second.
GLP-1s are simply the first place the math got loud enough to force a change. The same model works for any high-cost therapy. An employer or a health plan can carve out a category, set a defined contribution, point the wallet at the right drug list, and move the whole thing to real-time pricing and payment.
For the employer, spend becomes predictable and capped. For the member, a high-cost drug becomes affordable, with a simple checkout instead of a paperwork maze. For manufacturers and direct channels, a clean way to reach the people who need them. For the health plan, control without friction.
The Lynx Rx Access Wallet is the neutral rail in the middle that lets all of it happen, in real time, for GLP-1s and whatever high-cost therapy comes next.